Last reviewed · How we verify
Nystatin 10000U/ml
Nystatin binds to ergosterol in fungal cell membranes, creating pores that cause leakage and cell death.
Nystatin binds to ergosterol in fungal cell membranes, creating pores that cause leakage and cell death. Used for Oral candidiasis (thrush), Cutaneous and mucocutaneous candida infections, Intestinal candidiasis.
At a glance
| Generic name | Nystatin 10000U/ml |
|---|---|
| Also known as | Mycostatin (Amman Pharmacuetical Corp. Amman, Jordan |
| Sponsor | Riyadh Colleges of Dentistry and Pharmacy |
| Drug class | Polyene macrolide antifungal |
| Target | Ergosterol |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Nystatin is a polyene macrolide antibiotic that selectively targets ergosterol, a sterol unique to fungal cell membranes. By binding to ergosterol, it disrupts membrane integrity and increases permeability, leading to loss of cellular contents and fungal cell death. It is fungicidal and has minimal effect on mammalian cells due to their reliance on cholesterol rather than ergosterol.
Approved indications
- Oral candidiasis (thrush)
- Cutaneous and mucocutaneous candida infections
- Intestinal candidiasis
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Local irritation or burning (topical)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nystatin 10000U/ml CI brief — competitive landscape report
- Nystatin 10000U/ml updates RSS · CI watch RSS
- Riyadh Colleges of Dentistry and Pharmacy portfolio CI